Patients with malignant mesothelioma may be eligible to participate in a new clinical trial at the NIH Clinical Center.
Raffit Hassan, M.D., of the Thoracic and GI Malignancies Branch is leading a study of a combination treatment for malignant mesothelioma. This type of cancer develops in the thin layer of tissue lining the chest or abdomen, often following exposure to airborne asbestos particles. In this study, patients will first receive an immunotoxin called LMB-100. This is a targeted immunotherapy that delivers a substance toxic to cancer cells that make a protein called mesothelin. Mesothelioma cells have an abnormally high amount of mesothelin on their surfaces. The second drug in the combination treatment is pembrolizumab. This immunotherapy agent blocks a protein pathway that allows cancer cells to hide from the immune system. By doing so, pembrolizumab helps the immune system to detect and attack cancer cells. Investigators want to see how well patients with mesothelioma respond to this combination treatment.
Clinicaltrials.gov identifier: NCT03644550
NCI Protocol ID: NCI-18-C-0136
Official Title: Phase II Study of the Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.